Cargando…
Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation
OBJECTIVE: This study was to explore the most appropriate radiomics modeling method to predict the progression-free survival of EGFR-TKI treatment in advanced non-small cell lung cancer with EGFR mutations. Different machine learning methods may vary considerably and the selection of a proper model...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008953/ https://www.ncbi.nlm.nih.gov/pubmed/35422007 http://dx.doi.org/10.1186/s13104-022-06019-x |
_version_ | 1784687172386816000 |
---|---|
author | Zhu, Jian-man Sun, Lei Wang, Linjing Zhou, Tong-Chong Yuan, Yawei Zhen, Xin Liao, Zhi-Wei |
author_facet | Zhu, Jian-man Sun, Lei Wang, Linjing Zhou, Tong-Chong Yuan, Yawei Zhen, Xin Liao, Zhi-Wei |
author_sort | Zhu, Jian-man |
collection | PubMed |
description | OBJECTIVE: This study was to explore the most appropriate radiomics modeling method to predict the progression-free survival of EGFR-TKI treatment in advanced non-small cell lung cancer with EGFR mutations. Different machine learning methods may vary considerably and the selection of a proper model is essential for accurate treatment outcome prediction. Our study were established 176 discrimination models constructed with 22 feature selection methods and 8 classifiers. The predictive performance of each model were evaluated using the AUC, ACC, sensitivity and specificity, where the optimal model was identified. RESULTS: There were totally 107 radiomics features and 7 clinical features obtained from each patient. After feature selection, the top-ten most relevant features were fed to train 176 models. Significant performance variations were observed in the established models, with the best performance achieved by the logistic regression model using gini-index feature selection (AUC = 0.797, ACC = 0.722, sensitivity = 0.758, specificity = 0.693). The median R-score was 0.518 (IQR, 0.023–0.987), and the patients were divided into high-risk and low-risk groups based on this cut-off value. The KM survival curves of the two groups demonstrated evident stratification results (p = 0.000). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-022-06019-x. |
format | Online Article Text |
id | pubmed-9008953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90089532022-04-15 Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation Zhu, Jian-man Sun, Lei Wang, Linjing Zhou, Tong-Chong Yuan, Yawei Zhen, Xin Liao, Zhi-Wei BMC Res Notes Research Note OBJECTIVE: This study was to explore the most appropriate radiomics modeling method to predict the progression-free survival of EGFR-TKI treatment in advanced non-small cell lung cancer with EGFR mutations. Different machine learning methods may vary considerably and the selection of a proper model is essential for accurate treatment outcome prediction. Our study were established 176 discrimination models constructed with 22 feature selection methods and 8 classifiers. The predictive performance of each model were evaluated using the AUC, ACC, sensitivity and specificity, where the optimal model was identified. RESULTS: There were totally 107 radiomics features and 7 clinical features obtained from each patient. After feature selection, the top-ten most relevant features were fed to train 176 models. Significant performance variations were observed in the established models, with the best performance achieved by the logistic regression model using gini-index feature selection (AUC = 0.797, ACC = 0.722, sensitivity = 0.758, specificity = 0.693). The median R-score was 0.518 (IQR, 0.023–0.987), and the patients were divided into high-risk and low-risk groups based on this cut-off value. The KM survival curves of the two groups demonstrated evident stratification results (p = 0.000). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-022-06019-x. BioMed Central 2022-04-14 /pmc/articles/PMC9008953/ /pubmed/35422007 http://dx.doi.org/10.1186/s13104-022-06019-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Note Zhu, Jian-man Sun, Lei Wang, Linjing Zhou, Tong-Chong Yuan, Yawei Zhen, Xin Liao, Zhi-Wei Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation |
title | Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation |
title_full | Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation |
title_fullStr | Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation |
title_full_unstemmed | Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation |
title_short | Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation |
title_sort | radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with egfr mutation |
topic | Research Note |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008953/ https://www.ncbi.nlm.nih.gov/pubmed/35422007 http://dx.doi.org/10.1186/s13104-022-06019-x |
work_keys_str_mv | AT zhujianman radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation AT sunlei radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation AT wanglinjing radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation AT zhoutongchong radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation AT yuanyawei radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation AT zhenxin radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation AT liaozhiwei radiomicscombinedwithclinicalcharacteristicspredictedtheprogressionfreesurvivaltimeinfirstlinetargetedtherapyforadvancednonsmallcelllungcancerwithegfrmutation |